Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study:

Holly R Keir, BSc Amelia Shoemark, PhD Alison J Dicker, PhD Lidia Perea, MSc Jennifer Pollock Yan Hui Giam, BSc et al.

17 February, 2021

NZ Respiratory Research Review Issue 191

Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis:

James D. Chalmers, M.B., Ch.B., Ph.D., Charles S. Haworth, M.B., Ch.B., M.D., Mark L. Metersky, M.D., Michael R. Loebinger, B.M., B.Ch., Ph.D., Francesco Blasi, M.D., Ph.D., Oriol Sibila, M.D., Ph.D., Anne E. O’Donnell, M.D., Eugene J. Sullivan, M.D., Kevin C. Mange, M.D., M.S.C.E., Carlos Fernandez, M.D., M.P.H., Jun Zou, Ph.D., and Charles L. Daley, M.D. for the WILLOW Investigators*

26 November, 2020

NZ Respiratory Research Review Issue 179

Airway Clearance Techniques in Bronchiectasis:

Ashwin Basavaraj, MD Radmila Choate, PhD, MPH Doreen Addrizzo-Harris, MD Byron Thomashow, MD Gregory Tino, MD Kevin L. Winthrop, MD, MPH et al.

2 July, 2020

Respiratory Research Review Issue 179

Cost of hospitalization for bronchiectasis exacerbation in children:

Vikas Goyal,Steven M. McPhail,Frank Hurley,Keith Grimwood,Julie M. Marchant,I. Brent Masters,Anne B. Chang

1 May, 2020

NZ Respiratory Research Review Issue 191

Association between physical activity and risk of hospitalisation in bronchiectasis:

Victoria Alcaraz-Serrano, Elena Gimeno-Santos, Giulia Scioscia, Albert Gabarrús, Adria Navarro, Beatriz Herrero-Cortina, Rosanel Amaro, Laia Fernández-Barat, Antoni Torres

3 March, 2020

Respiratory Research Review Issue 179

Improving outcomes for children with bronchiectasis and preventing it altogether:

Byrnes, C.

6 November, 2015

Presentation to Respiratory Conference New Zealand November 2015.

The impact of respiratory disease in New Zealand: 2014 update:

Telfar Barnard, L., Baker, M., Pierse, N., & Zhang, J.

4 April, 2015

This report covers six respiratory disease indicators: asthma, bronchiectasis, childhood bronchiolitis and pneumonia, chronic obstructive pulmonary disease (COPD), and total respiratory disease.

​Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease:

Martinez-Garcia, M., Carrillo, D., Soler-Cataluna, J., Donat-Sanz, Y., Serra, P., Lerma, M., et al.

7 February, 2013

Objectives: To assess the prognostic value of bronchiectasis in patients with moderate-to-severe COPD.

Respiratory health outcomes 1 year after admission with severe lower respiratory tract infection:

Trenholme, A. et al.

19 September, 2012

The aim of this study was to determine and to describe the presence of respiratory morbidity in young children 1 year after being hospitalized with a severe LRI.

Bronchiectasis secondary to primary immunodeficiency in children: Longitudinal changes in structure and function:

Haidopoulou, K., Calder, A., Jones, A., Jaffe, A., & Sonnappa, S.

9 June, 2009

​Primary immunodeficiency is a common cause of bronchiectasis in children. The term bronchiectasis suggests an irreversible process; however, disease progression following treatment is controversial. The aim of this study was to evaluate the progression of bronchiectasis in children with primary immunodeficiency after institution of treatment. The authors concluded that bronchiectasis secondary to primary immunodeficiency in childhood is not always a progressive condition, suggesting a potential to slow or prevent disease progression with appropriate treatment.